Retractable Technologies, Inc. — FY2022 Form 10-K
Reporting period: Fiscal year ended December 31, 2022. Although the request identifies 2022 Q4, this is an annual filing; the supplied filing text does not provide standalone fourth-quarter financial results. The company manufactures and markets safety medical products, principally retractable syringes, under brands including VanishPoint. It operates as one reportable segment.
Financial performance and position
| Metric | FY2022 | FY2021 |
|---|---|---|
| Net sales | $94.8 million | $188.4 million |
| Gross profit / gross margin | $28.3 million / 29.8% | $95.4 million / 50.6% |
| Operating income (loss) / margin | ($0.9) million / (0.9%) | $72.6 million / 38.5% |
| Net income | $5.1 million | $56.1 million |
| Net income applicable to common shareholders; diluted EPS | $4.8 million; $0.15 | $55.8 million; $1.63 |
| Cash from operations | $16.8 million | $32.8 million |
- Sales fell 49.7%; total unit sales declined 38.9%. Domestic revenue decreased 68.8%, while international revenue increased 105% and represented 44.9% of sales.
- Cash and cash equivalents were $19.7 million, and investments in debt and equity securities were $29.7 million at year-end. Current assets were $88.8 million versus current liabilities of $12.1 million.
- Total debt was $1.8 million, including $0.3 million current. The loan is secured by company land and buildings and bore 7.75% interest at year-end. The separate $75.5 million TIA-related long-term liability reflects government-funded expansion costs, not conventional borrowing.
- Cash used in investing activities was $31.2 million; cash provided by financing activities was $5.0 million. Cash declined by $9.4 million during the year.
- Total assets were $195.7 million and stockholders’ equity was $106.5 million. The company reported a $10.6 million income-tax receivable, attributed to revised state tax estimates following a nexus study.
Material changes from FY2021
- COVID-19-related U.S. government sales fell to $15.7 million from $113.7 million, with 2022 sales concentrated in the first quarter as government orders wound down.
- International sales rose with vaccination activity occurring later than in the United States. Management cautioned that international revenue per unit is lower, potentially weighing on average selling prices and margins.
- Operating expenses increased 27.9%. General and administrative expense included $10.1 million of stock-option expense, including $5.5 million accelerated when awards were canceled in December. This was a significant non-cash charge.
- Freight and certain raw-material costs increased; higher freight costs affected comparability because prior U.S. government contracts included freight reimbursement.
- Cash from operations decreased from $32.8 million to $16.8 million. The 2022 amount benefited substantially from a $29.7 million reduction in accounts receivable, partly offset by lower accounts payable and the recognition of tax receivables.
Outlook, risks and unusual items
- Management gave no specific revenue or earnings guidance. It said it expected adequate resources to meet short-term operating needs for at least 12 months from issuance of the financial statements, using operations, cash reserves and investments if needed.
- Management believes domestic customers retained excess vaccination-related inventory; the timing of its depletion is uncertain, and domestic demand may remain depressed. Future U.S. government orders are also uncertain.
- Chinese manufacturers supplied approximately 91.6% of products in 2022. Trade policy, tariffs, logistics, supplier interruption and the ability to replace overseas production are material risks.
- VanishPoint syringes accounted for 91.5% of 2022 sales, creating product concentration and exposure to patent expiration, copying or competing technologies. Larger competitors have substantially greater resources.
- On March 22, 2023, after year-end, the company reduced its workforce by approximately 22%; it expects annualized wage savings of about $1.7 million, or 13% of 2022 wage expense, and separation costs of about $154,000.
- The company repurchased 3 million shares from BML Investment Partners for $4.8 million, or $1.60 per share, under a December 2022 private agreement. It also repurchased shares under a separate plan that ended in April 2022.
- A lawsuit against former legal counsel alleging malpractice and negligence remained pending; trial was postponed to October 30, 2023. The filing reports that the SEC would not pursue the company’s stock-trading manipulation concerns from an enforcement perspective.
- The independent auditor issued an unqualified opinion on the financial statements. Management concluded disclosure controls and internal control over financial reporting were effective; the auditor was not engaged to audit internal control.
Important facts for investors to verify
- Whether customer inventories clear and whether domestic demand recovers after the decline in COVID-19-related orders.
- Whether international sales growth can continue and how its lower per-unit revenue affects margins and profitability.
- Cash generation excluding working-capital movements, the recoverability and timing of the $10.6 million tax receivable, and the liquidity and valuation risks of the $29.7 million investment portfolio.
- Execution and utilization of expanded domestic capacity, the extent of ongoing TIA obligations, and dependence on Chinese production and suppliers.
- The impact of the workforce reduction, the completed option cancellation and future operating expenses; also confirm the terms and accounting for the private share repurchase.
- Developments in the pending legal case, unclaimed preferred-stock dividends of approximately $1.4 million, and the company’s patent protection and related-party technology license.